IMPROVE-IT Published: Ezetimibe Lowers LDL, Reduces EventsIMPROVE-IT Published: Ezetimibe Lowers LDL, Reduces Events
In an editorial, two experts argue IMPROVE-IT supports the LDL-cholesterol-lowering hypothesis—that lower LDL, regardless of how it is achieved, is better—and that there's nothing uniquely beneficial about ezetimibe. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 3, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK),
known as MSD outside the United States and Canada, today announced that
the New England Journal of Medicine published the results
of the IMPROVE-IT trial, an investigational study comparing treatment
with VYTORIN® (ezetimibe and simvastatin) to treatment with
simvastatin alone in more than 18,000 patients presenting with acute
coronary syndromes.
Language:
English
Co...
Source: Merck.com - Product News - June 3, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
How Marketing And Media Muddled The Truth About The Heart Drug Vytorin
Over the past eight years I’ve written more than 100 stories criticizing a drug called ezetimibe, which is sold by itself under the brand name Zetia and in combination with an older drug under the brand Vytorin. When I started off, in 2006, it was just “the Vytorin question:” did these (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 17, 2015 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
Dateline City:
SAN DIEGO
SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from a pre-specified exploratory analysis of the investigational
IMPROVE-IT study of more than 18,000 patients presenting with acute
coronary syndromes.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor...
Source: Merck.com - Product News - March 16, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Alirocumab Subcutaneously as Monotherapy vs EzetimibeAlirocumab Subcutaneously as Monotherapy vs Ezetimibe
Will a bi-weekly injection be what saves the day for patients with hypercholesterolemia? Future Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 5, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
Dateline City:
KENILWORTH, N.J.
Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new data from two trials of the company’s
cardiovascular medicines will be presented at the 2015 American College
of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San
Diego.
Language:
...
Source: Merck.com - Product News - February 25, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
IMPROVE-IT: Are We Back to 'The Lower the Better' for LDL-C?IMPROVE-IT: Are We Back to 'The Lower the Better' for LDL-C?
Seth Bilazarian and Chris Cannon discuss the role of ezetimibe in secondary prevention and whether super-low LDL-C levels are the way to go. theheart.org on Medscape (Source: theHeart.org)
Source: theHeart.org - December 1, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Friday Feedback: Will IMPROVE-IT Trial Affect Primary Care?
(MedPage Today) -- Study cast ezetimibe plus statin in a new light. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2014 Category: Cardiology Source Type: news
Zetia Shows Modest Benefit in Reducing Heart Attacks
Merck’s Zetia proved effective at reducing risk of heart attacks, strokes and other heart problems in a large, long-awaited trial. (Source: WSJ.com: Health)
Source: WSJ.com: Health - November 18, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
IMPROVE-IT: Modest Clinical Benefit from Ezetimibe (FREE)
By Larry Husten
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Adding ezetimibe to statin therapy in patients with an acute coronary event is associated with a small reduction in adverse cardiovascular outcomes, according to results of the IMPROVE-IT study presented Monday at the American … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 18, 2014 Category: Primary Care Source Type: news
Study Finds Alternative to Anti-Cholesterol Drug
The finding, which showed that the drug ezetimibe lowers LDL cholesterol, can help millions who cannot tolerate statins or do not respond to them sufficiently. (Source: NYT Health)
Source: NYT Health - November 17, 2014 Category: Consumer Health News Authors: By GINA KOLATA Tags: Heart Zetia (Drug) Cholesterol Vitorin Medicine and Health Statins (Cholesterol-Lowering Drugs) Source Type: news
What I'm Telling Patients About Ezetimibe (Zetia) on Monday What I'm Telling Patients About Ezetimibe (Zetia) on Monday
Dr Melissa Walton-Shirley summarizes the points of IMPROVE-IT for her patients. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2014 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
Merck's Zetia cuts heart attack, stroke risk in long-awaited study
CHICAGO (Reuters) - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin. (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
IMPROVE-IT: 'Modest' Benefit With Ezetimibe in Post-ACS PatientsIMPROVE-IT: 'Modest' Benefit With Ezetimibe in Post-ACS Patients
It's taken 9 years to learn whether or not adding ezetimibe to statins provide any clinical benefit in post-ACS patients. The answer: yes, it does, but the benefit is modest. What this means in the real world will likely be debated for many months to come. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
Regeneron drug highly effective for those who can't take statins: study
CHICAGO (Reuters) - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday. (Source: Reuters: Health)
Source: Reuters: Health - November 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
